Pyrotinib‐containing regimens have demonstrated significant efficacy and favorable safety in multiple pivotal studies and have been approved in China for first‐ and second‐line treatment of HER2‐positive advanced breast cancer as well as for neoadjuvant therapy in early‐stage HER2‐positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.